Format
Sort by

Send to

Choose Destination

Links from Books

Items: 1 to 20 of 124

1.

EVALUATION OF ASPIRIN IN TREATMENT OF HEADACHE.

MURRAY WJ.

Clin Pharmacol Ther. 1964 Jan-Feb;5:21-5. No abstract available.

PMID:
14107119
2.
3.

The treatment of chronic benign pain syndrome in capitated health care.

Kent J.

Manag Care Q. 1996 Spring;4(2):77-83.

PMID:
10157265
4.

Data briefing. Migraine.

Appleby J.

Health Serv J. 1996 Apr 11;106(5498):34-5. No abstract available.

PMID:
10156086
5.

Societal perspective on the burden of migraine in The Netherlands.

van Roijen L, Essink-Bot ML, Koopmanschap MA, Michel BC, Rutten FF.

Pharmacoeconomics. 1995 Feb;7(2):170-9.

PMID:
10155303
6.

The burden of migraine. A review of cost to society.

Lipton RB, Stewart WF, Von Korff M.

Pharmacoeconomics. 1994 Sep;6(3):215-21. Review.

PMID:
10155264
7.

Quality-of-life assessment in patients with headache.

Solomon GD.

Pharmacoeconomics. 1994 Jul;6(1):34-41. Review.

PMID:
10147352
8.

Healthcare resource and lost labour costs of migraine headache in the US.

Osterhaus JT, Gutterman DL, Plachetka JR.

Pharmacoeconomics. 1992 Jul;2(1):67-76.

PMID:
10146980
9.

The cost of migraine: more than just a headache?

Davey PJ, Leeder SR.

Pharmacoeconomics. 1992 Jul;2(1):5-7. No abstract available.

PMID:
10146975
10.

Special report. Controlling headache costs.

[No authors listed]

Bus Health. 1992;[HEADACHE]:6-30. No abstract available.

PMID:
10117919
11.
12.

Effectiveness of subcutaneous dihydroergotamine by home injection for migraine.

Becker WJ, Riess CM, Hoag J.

Headache. 1996 Mar;36(3):144-8.

PMID:
8984085
13.

Prescribing practices for the management of headache in Newfoundland and Labrador.

Furlong S, Pryse-Phillips W, Crowley M, Turner CJ.

Headache. 1996 Oct;36(9):542-6.

PMID:
8916562
14.

Impact of sumatriptan on clinic utilization and costs of care in migraineurs.

Litaker DG, Solomon GD, Genzen JR.

Headache. 1996 Oct;36(9):538-41.

PMID:
8916561
15.

Subcutaneous sumatriptan for the treatment of migraine: humanistic, economic, and clinical consequences.

Cohen JA, Beall DG, Miller DW, Beck A, Pait G, Clements BD.

Fam Med. 1996 Mar;28(3):171-7.

PMID:
8900548
16.

Recommendations for reporting cost-effectiveness analyses. Panel on Cost-Effectiveness in Health and Medicine.

Siegel JE, Weinstein MC, Russell LB, Gold MR.

JAMA. 1996 Oct 23-30;276(16):1339-41. Review.

PMID:
8861994
17.

Pattern of sumatriptan use and overuse in general practice.

Ottervanger JP, Valkenburg HA, Grobbee DE, Stricker BH.

Eur J Clin Pharmacol. 1996;50(5):353-5.

PMID:
8839655
18.

Headache epidemiology. Emphasis on migraine.

Silberstein SD, Lipton RB.

Neurol Clin. 1996 May;14(2):421-34. Review.

PMID:
8827180
19.

MIG ACCESS: a population-based, nationwide, comparative survey of access to care in migraine in France.

Michel P, Pariente P, Duru G, Dreyfus JP, Chabriat H, Henry P.

Cephalalgia. 1996 Feb;16(1):50-5; discussion 4. Erratum in: Cephalalgia 1996 May;16(3):213. Dreyfuss JP [corrected to Dreyfus JP].

PMID:
8825700
20.

Cost considerations in headache treatment. Part 2: Acute migraine treatment.

Von Seggern RL, Adelman JU.

Headache. 1996 Sep;36(8):493-502.

PMID:
8824005
Items per page

Supplemental Content

Support Center